Please login to the form below

Not currently logged in
Email:
Password:

Deal Watch table for May 2013

Table listing all the major pharma mergers, acquisitions and collaborations in the past month

This table lists all the major pharma collaborations, acquisitions and mergers during May 2013.

For an indepth analysis of these deals, read 'Pharma deals during May 2013'

Licensor acquired / licensee acquirer

Deal type

Product / technology

Headline ($m)

Bausch & Lomb/ Valeant

Company acquisition

Ophthalmology business

8,700

Warner Chilcott/ Actavis

Company acquisition 

Branded medicines for women's health, gastroenterology, derma

8,500

Theravance/ Elan Royalty Participation 21% of respiratory product royalties received by Theravance

1,000

Xellia/ Novo A/S  Company acquisition by Novo's VC arm API manufacturer and anti-infective products

700

AOP Orphan/ Elan Company acquisition Rare disease medicines $76m sales

693

Trevena/ Forest  

Option to license + equity

TRV027 phase 2 acute heart failure + $30m equity

460

Omthera/ AstraZeneca

Company acquisition 

Dyslipidemia therapy end phase III 443
Abide/ Merck & Co

Licence, collaboration 

Targets for Type II diabetes – 3 products 430
Okairos/ GSK

Company acquisition

Vaccine platform technology  325
Newbridge/ Elan

48 per cent company share 

UAE based regional company $40m + $244m option for 52% 284
Inviragen/ Takeda

Company acquisition 

Vaccines in phase I and II

250

Alexza/ Teva

Licence, supply US

Adasuve approved for acute agitation

235*

EKOS/ BTG

Company acquisition

Device for treating blood clots

220

Therasphere/ BTG

Asset purchase

Treatment for liver cancer

200

Aradigm/ Grifols 

Licence + equity

Inhaled ciprofloxacin phase III ready. 35 per cent of Aradigm ($26m)

116

Ambrx/ BMS Licence Develop and commercialise antibody drug conjugates

112

Elan/ Speranza Product spin out Product spin out ELND005 phase 2 CNS drug

70**

Alvine/ Abbvie

Option to acquire

Phase II product for celiac disease

70

Cempra / Toyama  Licence, development Solithromycin phase III 70***
Valeant / Actavis

Product acquisition

Metronidazole gel

55

Astellas / Amgen  Co-development / JV 5 Amgen development products ND***
Nimbus / Shire Co-development Lysosomal storage disorder agents ND

 

Unless noted all transactions are for global rights
*  US only
**  Payment by Elan not Speranza
*** Japan only

The Deal Watch table is compiled my Medius Associates

10th June 2013

The Deal Watch table is compiled my Medius Associates

10th June 2013

From: Research, Sales

Share

Tags


Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
McCann Health

The most globally awarded health agency network and currently Health Network agency of The Year. Comprising of two specialist agencies:...

Infographics